https://www.google.com/amp/s/www.urotoday.com/video-lectures/bladder-cancer/video/1771-blue-light-cystoscopy-with-cysview-for-management-of-non-muscle-invasive-bladder-cancer-joshua-meeks.amp.html

https://photocure.com/news/aua-abstracts-further-support-role-for-cysview-in-the-office-setting/

https://www.urologytimes.com/aua-annual-meeting/blue-light-cystoscopy-enables-earlier-detection-invasive-bladder-tumors

https://whatsupatupstate.wordpress.com/2020/05/11/science-is-art-is-science-shining-a-light-on-cancer/

NORNE HEVER KURSMÅLET TIL 150!

Even stronger LT growth prospects after Ipsen deal
Type:Result CommentAnbefaling:KjøpKursmål:150
We reiterate Buy recommendation on Photocure share at a higher TP of NOK 150/sh (130) after the news of taking back Hexvix from Ipsen makes it possible for the company to repeat the ongoing US success story in Europe. We see the company’s case strengthened by the news and visibility is better with clear guidance for 2023.

Transcript fra Q1.

https://finance.yahoo.com/news/edited-transcript-pho-ol-earnings-132444852.html

Ny oppdatert Topp 20 liste viser at halvparten av dem har økt siden mandagens liste.(Denne listen gjelder til og med handel mandag inneværende uke)
Avrundet til hele tusen og i rekkefølge etter hvor på Topp 20 dem befinner seg.
3. The Bank of NY Mellon SA/NV +58k
4. SEB Life Intern +100k
5. Nordnet Bank +33k
7. Danske Bank +1k
8. Nordnet Liv +35k
9. Verdipapirfondet FF Norge +14k
14. Verdipapirfondet Pareto Inv. +20k
17. Morgan Stanley & CO.LLC NY med 228k
19. KLP AksjeNorge Indeks + 3k
Societe Generale Paris UT

https://soundcloud.com/user-972208711/episode-129

Ny interessant video fra idag, 6.mai.

https://www.youtube.com/watch?v=mtkB4zJOjRg&fbclid=IwAR3GiYEGCU2h-qMFpVYcU6aytpvrDnrqxYYN3FrscZsSiTVndFxwwui-JyE&has_verified=1

Oppdatert Topp 20 gjeldende til og med torsdag i forrige uke.

Største endringer:

SEB + 100k til 530k og opp på 3.plass.

Societe Generale INN til 246k og 18.plass. Økning ukjent, men var UTE av Topp 50 på listen igår(som da gjaldt til og med onsdag)

Societe Generale Paris UT av Topp20.

Totalt antall aksjonærer i Photocure er nå 6869.(var under halvparten for under 1 år siden)

Kom i skade for å skrive at følgende hadde solgt seg ut:
SOCIETE GENERALE214
MORGAN STANLEY & CO. INTERNATIONAL
CITIBANK, N.A.
BURSKI KRZYSZTOF
FOLKES AS
FONDSAVANSE AS

Det er selvsagt ikke nødvendigvis riktig, de har blitt skjøvet ut av topp 50, korrigert tekst i innlegget over.

Oppdatert Topp 20 hvor det økes og endres etter emisjonen😀
NETTO økning Topp 50 forrige uke er 1,4 mill aksjer.

5.SEB LIFE INTERN ASSUR COMPANY DAC INN med 430k
14.VERDIPAPIRFONDET DELPHI NORDIC INN 255k
15.SOCIETE GENERALE PARIS INN 254k
17.VERDIPAPIRFONDET PARETO INVESTMENT INN 250k
40.ABN AMRO GLOBAL CUSTODY SERVICES INN 111k
46.AVANZA BANK AB INN 98k
47.SKANDIA NORDEN INN 96k

Følgende skyves ut av Topp 50 forrige uke:
SOCIETE GENERALE214
MORGAN STANLEY & CO. INTERNATIONAL
CITIBANK, N.A.
BURSKI KRZYSZTOF
FOLKES AS
FONDSAVANSE AS

https://photocure.com/investor/largest-shareholders/

Onsdag spiller Radforsk inn 2 podcast. Schneider og Erik Dahl fra Photocure blir med i den ene.
Kan være vel verdt å få med seg sett i lys av siste tids hendelser 😀👍

https://twitter.com/radforsk/status/1256880037086756865?s=20

Detecting Invisible Bladder Cancers with Blue Light Cystoscopy - Beyond the Abstract
April 27, 2020
Blue-light cystoscopy (BLC) is a photodynamic diagnostic technique that augments the detection of occult disease missed under traditional white light. Instillation of hexaminolevulinate, a heme precursor, causes preferential accumulation of protoporphyrin IX and other photoactive porphyrins in neoplastic cells, which are then excited under the wavelength of blue light (~450 nm) to fluoresce red. The sensitivity of BLC in detecting cancerous lesions is much higher than that of white-light alone (91% vs. 76%) and used together, BLC plus WLC has a sensitivity of 98.5%.1 
A recent phase III prospective multicenter study found that 20.6% of bladder malignancies were visualized solely under blue-light and would have been missed with WLC alone, consistent with other prospective BLC trials.2 Compared to standard WLC, BLC increases detection rates of papillary malignancy by 12% and CIS by 43%. In this trial, the improved detection rate and increased accuracy of risk stratification after BLC led to a change in management in 14% of patients who would have been under-staged and under-treated with WLC alone.3 The rate of false positive lesions is comparable between WLC and BLC (approximately 25-30%). In a subset of 13 patients who had recurrent high risk disease that was detected by BLC only, none had positive urine cytology, suggesting that though urinary cytology has high specificity, the sensitivity in high grade diseases may not be sufficient.
BLC has virtually no known toxic effects and patients report decreased anxiety and would recommend it to others.2,4 Following the positive data coming from large clinical trials, the addition of BLC in various settings is currently supported by the American Urological Association-Society of Urologic Oncology and the European Association of Urology.3 Expert recommendations currently support the use of BLC in post-treatment surveillance, as literature has demonstrated a survival benefit and decrease in recurrence rates with its incorporation.1,3
Our experience with this patient suggests an additional role for BLC in the initial diagnosis. There remain unanswered questions regarding the role of BLC in patients with non-muscle invasive BC at high risk for progression to invasive disease. In a recent review of the Cysview registry of over 3,500 lesions from over 1,200 patients, 23% of lesions were only visible under blue light and 14% of these lesions were muscle-invasive and would not have been detected otherwise (unpublished data). Early detection of disease is associated with a decrease in disease morbidity and mortality by increasing the utility of bladder-sparing therapies in non-muscle invasive disease and facilitating earlier delivery of neoadjuvant chemotherapy and radical cystectomy in muscle-invasive disease. This is of particular importance, considering the recurrence rate of non-muscle-invasive bladder cancer is 50-70%, and approximately 10-20% of patients will progress to muscle-invasive disease.5 Enhanced cystoscopic techniques have proven critical for earlier detection and accurate staging of both initial and recurrent cases.
Written by: Nima Nassiri, MD; Marissa Maas, BS; Kian Asanad, MD; Siamak Daneshmand, MD, Institute of Urology. Keck School of Medicine. University of Southern California. Los Angeles, CA
Disclosure: Dr. Daneshmand is a paid consultant for PhotoCure
References:




https://twitter.com/UrologyofVA/status/1255897222098673666?s=20

https://www.springermedizin.de/blue-light-cystoscopy-indications-and-outcomes/17866064?fbclid=IwAR2d2k4fm4oa4Eo9qIs2qEnW0yurchIKhrScrkGxaU2UMfQ3Wetd7GW39UM

Ny Radium podcast nettopp sluppet.
Photocure omtales fra start!

Hexvix rettighetene, emisjonen og Antonsen.

https://soundcloud.com/user-972208711

https://photocure.com/news/photocure-asa--board-member-resignation/

Ja, dette er vel en av HS sine menn etter hva jeg har skjønt her på forumet.

https://photocure.com/news/photocure-asa-mandatory-notification-of-trade3/

https://photocure.com/news/photocure-asa--new-share-capital-registered/

https://twitter.com/JEinarsson/status/1255056503700180995?s=20

Blue light cystoscopy fra 28:55.

https://www.youtube.com/watch?v=ZLQutCwc1S4&fbclid=IwAR1iAV85r2Eu6F9nDvUuHEsnSmchtq9-WLlcd8_lL1Qq7KNflOVzb8fZiuE

https://www.google.com/amp/s/www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/121102-detecting-invisible-bladder-cancers-with-blue-light-cystoscopy-beyond-the-abstract.amp.html

Emi kurs 65,50, SPREKT!
Og, overtegnet flere ganger.

The subscription price was determined through an accelerated bookbuilding process after close of trading on 27 April 2020. The Private Placement attracted very strong interest from existing shareholders, as well as from new high quality institutional investors. The Private Placement was multiple times oversubscribed.

https://photocure.com/news/photocure-asa--private-placement-successfully-placed/

Dagens to meldinger samt litt twittermeldinger.

https://photocure.com/news/photocure-regains-worldwide-rights-of-hexvix/

https://photocure.com/news/photocure-asa---contemplated-private-placement/

https://twitter.com/pharminews/status/1254800429352980487?s=20
https://twitter.com/zimp_a/status/1254798039409135616?s=20
https://twitter.com/PhotocureASA/status/1254797096378675201?s=20

IFBM. emisjonen har selskapet lagt ut en presentasjon og derav også tallene for q1.
Tallene er foreløpige og ikke ferdig revidert.

https://photocure.com/globalassets/investor-relations/presentations/photocure--company-update--27-april-2020.pdf

Har ikke sjekket transcript, men mener å huske at det var under q&a session ifbm q3 at DS snakket om diverse kjeder og han sa det på en måte som at det ikke trengte være nødvendigvis Kaiser som kommer først. Med det jeg oppdaget på Cysview.com idag heller jeg faktisk mot VA.

https://www.cysview.com/info-for-hcps/for-vamcs/#

Ny aksjonærliste tatt ut idag viser netto økning Topp 20 med ca. 63k. Alle endringer oppgitt i cirka.

2. Verdipapiret KLP AksjeNorge - 17k

3. The Bank of NY +31k

4. J.P Morgan Sec. + 81k

5. Nordnet Bank + 15k

6. Danske Bank + 2k

7. Morgan Stanley - 22k

8.Kommunal Landsp.kasse - 10k

10. Nordnet Liv. - 20k

17. KLP AksjeNorge Indeks + 3k

Viser også at det nå er totalt 6669 aksjonærer i selskapet.

6 nye klinikker oppført på Cysview.

Veteran Health Indiana
1481 W. 10th Street Indianapolis, IN 46202

Sacramento VA Medical Center - VA Northern California Health Care System
10535 Hospital Way, Mather, CA 95655

Bruce W. Carter VA Medical Center
1201 NW 16th St, Miami, FL 33136

Washington DC VA Medical Center
50 Irving St. NW. Washington, DC 20422

West Palm Beach VA Medical Center
7305 N Military Trl, West Palm Beach, FL 33410

Wilmington VA Medical Center
1601 Kirkwood Hwy, Wilmington, DE 19805

"Follow-up treatment: This depends on the pathology report. If the tumor was superficial, (under three centimeters), and not aggressive, you’ll need a follow-up cystoscopy three months after the surgery, preferably via a blue-light cystoscopy instead of the standard white-light cystoscopy. These probes use different wavelengths and filters that can help urologists see smaller tumors more easily."

https://www.healthcentral.com/condition/bladder-cancer-treatment

https://twitter.com/urotoday/status/1250472766786228226?s=20

https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/120567-blue-light-cystoscopy-indications-and-outcomes.html

Ny klinikk oppført på Cysview.
Deaconess Clinic Urology.
209 Gateway Blvd Newburgh, IN 47630

https://photocure.com/news/photocure--employee-incentive-program/

https://photocure.com/news/photocure-asa--annual-accounts-2019/

https://twitter.com/PhotocureASA/status/1247544398595923972?s=20

https://photocure.com/news/photocure-asa-market-update-2/

https://photocure.com/news/photocure-asa-market-update/

GU Cancers 2020 | Blue light cystoscopy for bladder cancer

Sima Porten

Sima Porten, MD, MPH, FACS, University of California, San Francisco, CA, discusses a study on blue light cytoscopy with cysview (BLCC) at the UCSF (NCT02660645). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

https://twitter.com/VJOncology/status/1246734342061281281?s=20

Nytt fra Asieris igår.
Finner den dessverre bare i et word dokument, Cevira er omtalt litt nedenfor.
Finnes også på kinesisk. http://www.asieris.cn/index.php/content/186?fbclid=IwAR2ybGL08Srk8kFn8CHW6oziIzlpLvjbMOHJosOFv-Rnw9luJPtz5y_yNZw



Asieris 24-03-2020
Yahong Pharmaceutical announces the completion of Series C financing to accelerate the development of the world's first innovative drug
Time: 2020-03-24
Shanghai, China, March 24, 2020-Yahong Pharmaceutical Technology Co., Ltd. ("Yahong Pharmaceutical") today announced the completion of Series C financing, raising hundreds of millions of yuan in capital, and the C + round of financing will also be completed in the near future. This round of financing was led by Yanyuan Innovation Capital, followed by investment institutions such as Interchina Venture Capital and Yifeng Capital. Round B investment institutions Beijing Longpan and Kaitai Capital continued to invest in this round through cooperative funds. The funds raised will be used to support the company's multiple independent research and development projects.

The key project of Yahong Pharmaceuticals APL-1202 is the national “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan for Major New Drug Creation Projects”. It is the world's first innovative drug for oral treatment of non-muscle invasive bladder cancer that has entered registered clinical development. At present, the standard drug treatment method for preventing recurrence of non-muscle invasive bladder cancer after surgery is bladder infusion chemotherapy or BCG. The whole process is very painful and the adverse reactions are serious. APL-1202, as a new oral antitumor mechanism, is convenient, painless, and harmless to the urethra. It will help patients avoid or delay the fate of total bladder resection. APL-1202 has completed the phase III clinical trial of all patients in China, and also completed the phase I clinical trial in the United States. The phase II clinical trial in the United States is about to start.

Cevira®, a photodynamic drug combination product for non-surgical treatment of cervical precancerous lesions, which is being developed by Yahong Pharmaceutical, will also start the China-US-Europe International Multi-Center III clinical trial, mainly for Chinese patients, in 2020. Cevira® is targeted to treat patients 18 years of age and older who have a histopathologically proven high-grade cervical squamous intraepithelial lesion (HSIL). The current standard treatment for these patients is surgery. The most common treatments include cervical circular resection (LEEP / LLETZ) and cold-knife cone resection (CKC). However, these surgical treatments have adverse reactions, including bleeding. , Infection, cervical organic damage caused by a series of subsequent effects on fertility, such as premature delivery, abortion and so on. Therefore, Cevira® will provide a new treatment option for Chinese and global patients, so that some patients can avoid the pain and side effects of surgical treatment, especially the risk of future pregnancy. Cevira® has also won the Fierce Life Science Innovation Award with the international reputation of the best medical device innovation award 2019.

Yahong Pharmaceutical's other research project APL-1501 also belongs to the country's "13th Five-Year Plan for Major New Drug Development". This project mainly focuses on the treatment of multi-drug resistant infections. Compared to traditional antibiotics, APL-1501 has a new antibacterial mechanism and has good bactericidal activity against broad-spectrum Gram-positive and negative drug-resistant bacteria. And it has shown good efficacy in animal models of systemic multidrug resistance infection. APL-1501 is of great significance in addressing the severe challenge of no drug treatment after multidrug resistance infections facing the world, especially in China. In addition to multiple independent research and development of new drug projects and exclusive technology platforms, Yahong Pharmaceutical also negotiates with many domestic and foreign biopharmaceutical companies to develop cooperation in China and overseas markets.

Dr. Pan Ke, co-founder and CEO of Yahong Pharmaceutical, said: "This Series C financing led by Yanyuan Innovation Capital has provided strong support for the subsequent development of Yahong Pharmaceutical, and we are very grateful to investors for their support. Recognition of Rainbow Pharmaceutical's R & D strategies, projects and technologies. After ten years of accumulation, 2020 will be a year of rapid development for Yahong Pharmaceutical, and many projects will soon complete clinical trials or apply for new drug certificates. Yahong Pharmaceutical will also embark on a new The journey from the R & D company to the pharmaceutical company integrating research, production and sales will bring innovative therapeutic drugs and better treatment methods to more patients as soon as possible. "

Yanyuan Innovation Capital has always been adhering to the concept of value investment. In recent years, it has vigorously deployed life and health, especially biomedicine, medical equipment and other sub-sectors. Liu Zeng, President of Yanyuan Innovation Capital, commented, "Yahong Pharmaceuticals has a rich product pipeline layout and unique technology platform, and has breakthrough potential in its focus on the field of urogenital tumors. We believe that Dr. Pan, led by Hong The team can fully combine the advantages of domestic and foreign technologies, talents, capital and markets to make Yahong Pharmaceutical into a leading pharmaceutical company at home and abroad. We are glad to participate in the growth of Yahong together. "

Since its establishment in 2010, Yahong Pharmaceutical has been adhering to the belief of "improving human health and making life more dignified", and is committed to becoming the most innovative and influential pharmaceutical company in the field of focus and respect and trust. Yahong Pharmaceutical's business is located in Shanghai, Beijing, Jiangsu Taizhou Medical City and the United States.At the same time, it has established a research and development center in Shanghai and has established an international professional R & D technical team, focusing on anti-tumor and related diseases of the urogenital system. Global innovative drug research and development. Yahong Pharmaceutical's previous rounds of A and B financing have been led by well-known venture capital institutions such as Taifu Capital and Beijing Longpan.



About Yahong Pharmaceutical
Yahong Pharmaceutical was established in March 2010 in China Medical City, Taizhou City, Jiangsu Province, and established a research and development center in Shanghai. It is a global innovative drug research and development company focusing on anti-tumor and related diseases of the urogenital system in China. Yahong Pharmaceutical is determined to become the most innovative and influential pharmaceutical company in the field of focus, most respectable and trustworthy. The company focused on the urogenital field and quickly established a leading position in this field and carried out a deep strategic layout. Yahong Pharmaceutical fully explores the global value of first-in-class new drugs with independent research and development and breakthrough therapeutic potential, while introducing new drugs that are already in the late stage of development overseas or have been launched into the Chinese market, improving product pipeline diversification and synergy, Quickly establish a leading position in the domestic market.

About Yanyuan Innovation Capital
Yanyuan Innovation Capital, formerly known as "Yanyuan Capital Group", was founded in June 2010. With the support of the Peking University Science and Technology Development Department, it is a high-tech enterprise jointly established by Peking University alumni who are engaged in venture capital investment and university technology achievement transformation. Investment and capital operation platform, currently has three major business segments of equity investment, securities investment, listed company cooperation and mergers and acquisitions reorganization. The headquarters is located in Beijing. It was established in Ningbo, Zhejiang in 2015, Hangzhou office in 2018, and Shanghai office in 2019. Close to 70 people. The overall management scale of venture capital funds, industrial funds, parent funds, and securities funds managed directly or indirectly by Yanyuan Innovation Capital has exceeded RMB 6 billion; 5 private equity fund managers have been registered, and more than 30 private equity funds have been registered Over 50 foreign investment projects, and more than 10 companies have been listed and declared to be listed in the past three years. The investment fields cover such industries as biomedicine, advanced manufacturing, and new-generation information technology. In 2019, there were 2 companies in the biomedical field in the invested companies listed on the science and technology board, of which Zeyu Pharmaceutical led by Yanyuan Innovation Capital was the first company in the science and technology board to declare and list on the fifth set of standards. Unprofitable biopharmaceutical company.

About Interchina Ventures
Shenzhen Guozhong Venture Capital Management Co., Ltd. is a private equity investment agency specializing in the management of venture capital investment trusts. Interstate Venture Capital advocates the investment concept of research first, combining investment with research. Guide the investment through in-depth research on the industry chain, focus on investment opportunities in strategic emerging industries, and focus on investing in outstanding companies in the three major areas of technological innovation, biomedical health, and TMT.

About Yifeng Capital
Yifeng Capital is a professional institution focusing on VC and PE investment in biomedicine. It uses a global perspective to deeply d

https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/120183-developments-in-the-follow-up-of-nonmuscle-invasive-bladder-cancer-what-did-we-learn-the-last-24-months-a-critical-review.html

In addition, Cevira, a photodynamic drug combination product that is being developed for the non-surgical treatment of cervical precancerous lesions, which is being developed by Yahong Pharmaceutical , will also start a China-US-Europe International Multi-Centre III clinical trial, mainly for Chinese patients. This product is used to treat patients with a high-grade cervical squamous intraepithelial lesion (HSIL) confirmed histopathologically by the histopathology of 18 years and older .

http://www.myzaker.com/article/5e796779b15ec0245c4b06e7/?fbclid=IwAR3kgkufSJPZx83ziEu37FsQ5Vv7t0VPuH935gAPZZsnsD3r83gKiqKlCek

Glemte denne i farten igår.

https://photocure.com/news/photocure-asa-market-update/